| Literature DB >> 34051332 |
Maria Guadalupe Martinez1, Anders Boyd2, Emmanuel Combe1, Barbara Testoni1, Fabien Zoulim3.
Abstract
Current antiviral therapies, such as pegylated interferon-α and nucleos(t)ide analogues, effectively improve the quality of life of patients with chronic hepatitis B. However, they can only control the infection rather than curing infected hepatocytes. Complete HBV cure is hampered by the lack of therapies that can directly affect the viral minichromosome (in the form of covalently closed circular DNA [cccDNA]). Approaches currently under investigation in early clinical trials are aimed at achieving a functional cure, defined as the loss of HBsAg and undetectable HBV DNA levels in serum. However, achieving a complete HBV cure requires therapies that can directly target the cccDNA pool, either via degradation, lethal mutations or functional silencing. In this review, we discuss cutting-edge technologies that could lead to non-cytolytic direct cccDNA targeting and cure of infected hepatocytes.Entities:
Keywords: HBV cure; cccDNA; chronic hepatitis B; direct-acting antivirals
Mesh：
Substances：
Year: 2021 PMID： 34051332 DOI： 10.1016/j.jhep.2021.05.013
Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 25.083